-
Immunotherapy
in ActionsThe new wave of immunotherapy antibodies in cancers and rare haematological diseases -
ElsaLys BiotechA clinical stage immuno-oncology company that designs and develops
a new generation of therapeutic antibodies
Welcome to ElsaLys Biotech
ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.
Today ELSALYS BIOTECH is conducting 5 proprietary development programs including LEUKOTAC®, an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.
The company is acting today in 3 main medical fields :
"LEUKOTAC® has a role to play in the management of steroid-resistant acute graft-versus-host disease (SR-aGvHD) with a considerable decrease of mortality in these patients.
LEUKOTAC® will be used in SR-aGvHD with no doubt, because of our huge experience of this drug. Once it is available again, it will be administrated and we can think about its potential use in the first line of treatment"
Pr. Mauricette Michallet
Previously Head of Haematology Unit Lyon Civil Hospices, Today in charge of post cancer at the Centre Léon Bérard
New Updates
Discover our latest news regarding our pipeline, our partnerships and more
Copyright 2018 ElsaLys Biotech SA